Revier Therapeutics develops small-molecule medicines targeting class IIa HDAC enzymes for cardiometabolic diseases.
High-Tech Gründerfonds
Activity from announced rounds
High-Tech Gründerfonds is a venture platform backing German and European technology businesses from pre-seed through growth, across deep tech, life sciences and digital technology.
Its specialist investment areas separate industrial, climate and deep technology from life sciences and chemistry, and from digital technology. That structure accommodates companies with scientific development and industrial deployment requirements alongside software businesses.
HTGF’s mandate includes technologies that are early, complex or require a long development horizon. Its team combines technical specialists and startup operators, connecting research-led founders with financing and an industrial investment network as they commercialise their work.
Sources
- Rounds participated in
- 7
- Confirmed lead rounds
- 0 6 roles undisclosed
- New companies
- 7 First participation on record · 0 follow-on
- Funding in participating rounds
- $37.2M 7 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
7 in this selectionMachine learning platform predicting crop variety performance for climate-smart breeding
Develops nanostructured sensor chips for rapid pathogen detection in food
Develops biofabricated human tissue implants and aims to manufacture 3D-printed organs
Developing fungal-based biological crop protection solutions using AI-driven discovery platform
Develops customised enzyme solutions for converting biomass into sustainable raw materials
Cancilico develops AI diagnostic software for hematology.